Since 2015, 3 immune checkpoint inhibitors targeting PD-1/PD-L1, nivolumab, pembrolizumab, and atezolizumab, were approved for second-line treatment of advanced NSCLC (8–11). The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.